Will (@medtechmd) header
Will (@medtechmd) profile picture

Photo: William Stewart Halsted : Father of modern surgery.

Florida, USA
Joined July 2011
$INSM: “Big picture: One of the more bullish mgmt meetings we've had so far at JEF London... we feel good on the $INSM trajectory and not surprised to see market appreciating this today too.”
1
7
27
3,076
$NUVB : Under the stewardship of CEO David Hung.
2
405
CNBC today: Treasury Secretary Scott Bessent on Sunday called for a “dramatic shakeup” at Nvidia after CEO Jensen Huang’s resignation, questioning whether the chipmaker pursued illicit sales of its advanced artificial intelligence chips to boost earnings. Bessent said Nvidia’s board should look outside the company for its next chief executive and suggested other executives should face scrutiny over the chip giant’s compliance with U.S. export controls. “I want to keep coming back to what was the culture at Nvidia, and were they pressing these seemingly illicit sales to goose their revenues and their earnings?” Bessent said in an interview on Fox News. From my HTS letter a decade ago: Here’s an August 20, 2001 story on Nvidia in EBN magazine titled: “Nvidia continues to swim against the tide, racking up record revenue, earnings.” The subtitle was “Magic formula’: superior design, execution.” From the heart of the story: “The fact that the Santa Clara Calif. graphics processor maker is excelling amid a contracting PC market and one of the worst semiconductor business cycles ever is leading analysts and observers to ask whether Nvidia can do no wrong.” I wasn’t convinced. My notes showed skepticism and there was concern about huge percentages of quarterly sales to a relatively unknown Taiwan-based company called EDOM. But in the following year (2002), Nvidia’s stock plummeted 90% (from 72 to 7.20, not adjusting for splits). All of a sudden there were excess inventories and revenue guide-downs. Additionally, there was an SEC probe of the company’s accounting practices. Nvidia’s CFO, Christina Hoberg, was “taking a leave of absence.” The SEC later brought charges of financial reporting fraud against the CFO, alleging the accounting fraud was done to meet Wall Street financial estimates. Hoberg neither admitted or denied wrongdoing but agreed to pay a $671,000 fine and be barred from serving as an officer or director of a public company for five years. As long-time readers of my HTS letter know, I've never trusted Mr. Leather Jacket. cnbc.com/2026/11/15/bessent-…
9
25
4
128
16,559
$INSM : Brinsupri October Symphony Data Suggest Strong Start To 4Q. Jefferies.
5
25
3,104
$HTFL : Cardiac imaging use may extend well beyond coronary artery diagnostics.
1
2
551
Jefferies expects “fast uptake” for $TAK Orexin product ORZEYFUL in NT1 vs $JAZZ Oxybate.
1
355
$MGTX : “We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP.” share.google/3jkkmHX36h5l2nf…
1
268
$MBX : Awaiting data related to long acting once monthly obesity molecule.
1
306
Will retweeted
$KURA KOMZIFTI® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market – – Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expanding development of ziftomenib in AML – – FDA alignment for approximately 40-patient monotherapy registrational study of darlifarnib in HRAS-mutated salivary gland cancer; study initiation targeted for 1H 2027 – – Darlifarnib combination studies in renal cell and pancreatic cancers expected to reach key development milestones in 2027 – – Strong financial position, supported by $492.1 million in cash, cash equivalents and short-term investments, anticipated Kyowa Kirin collaboration payments and up to $300 million additional financing capacity from Oberland Capital – – Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT –
1
3
2
34
11,002
$HUMA : How not to manage a company with a breakthrough, cutting-edge technology and product.
2
528
$MBX : Investors await once monthly obesity injection data.
1
1
6
1,097
$XENE : Jefferies positive take on AZK FOS/MDD/BPD progression.
1
2
11
2,384
The fact that China targeted Jensen underscores the geopolitical significance of AI leadership. That means both Democrats and Republicans will need to build lots of data centers. $NVDA
121
148
21
1,631
108,860
$TMDX : Competitive threat not affecting TMDX vertically integrated “moat”.
Jefferies $TMDX : Reiterates Buy $125.00 price target.
17
863
Jefferies $TMDX : Reiterates Buy $125.00 price target.
3
1
12
1,381
“The third quarter of 2026 was the strongest in TransMedics' history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO." $TMDX
1
3
13
1,128